1,719 results match your criteria empagliflozin


Sodium-Glucose Cotransporter-2 Inhibitors and Risk of Diabetic Ketoacidosis Among Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis.

Can J Diabetes 2021 Apr 28. Epub 2021 Apr 28.

Department of Medicine, Sinai Health System and the University of Toronto, Toronto, Ontario, Canada; Department of Medicine, General Internal Medicine, University of Toronto, Toronto, Ontario, Canada.

Objectives: The magnitude and precision regarding the risk of diabetic ketoacidosis (DKA) with sodium-glucose cotransporter-2 (SGLT2) inhibitors is unclear. Thus, we examined the risk of DKA with SGLT2 inhibitors in both observational studies and large clinical trials.

Methods: Searches were performed in PubMed, Embase, CENTRAL and Google Scholar (from inception to April 15, 2019) without language restrictions, including conference proceedings and reference lists. Read More

View Article and Full-Text PDF

Effect of anti-hyperglycemic drugs on endoplasmic reticulum (ER) stress in human coronary artery endothelial cells.

Eur J Pharmacol 2021 Jun 8:174249. Epub 2021 Jun 8.

Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Florida Jacksonville College of Medicine, Jacksonville, FL.

Endoplasmic reticulum (ER) stress plays a critical role in progression of diabetes and development of complications, notably cardiovascular disease. Some of the contemporary anti-hyperglycemic drugs have been shown to inhibit ER stress. To extend these observations, the effects of various anti-hyperglycemic agents were screened for their effects on ER stress. Read More

View Article and Full-Text PDF

Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage.

Am J Nephrol 2021 Jun 10:1-11. Epub 2021 Jun 10.

Cardiovascular Research, Research and Early Development, R&D Pharmaceuticals, Bayer AG, Wuppertal, Germany.

Introduction: The nonsteroidal mineralocorticoid receptor (MR) antagonist finerenone and sodium-glucose cotransporter-2 (SGLT2) inhibitors have demonstrated clinical benefits in CKD patients with type 2 diabetes. Clinical data analyzing the potential value of a combination therapy are currently limited. We therefore investigated cardiorenal protection of respective mono- and combination therapy in a preclinical model of hypertension-induced end-organ damage. Read More

View Article and Full-Text PDF

Empagliflozin Alleviates Atherosclerosis Progression by Inhibiting Inflammation and Sympathetic Activity in a Normoglycemic Mouse Model.

J Inflamm Res 2021 31;14:2277-2287. Epub 2021 May 31.

Department of Cardiology, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, 210008, Jiangsu, People's Republic of China.

Background: Recent clinical studies have revealed that sodium glucose co-transporter 2 inhibitors (SGLT2i) reduced cardiovascular events in type 2 diabetes. Here, we investigated whether empagliflozin, as a kind of SGLT2i, could alleviate atherosclerosis progression in non-diabetic mice.

Methods: -/- mice were fed on a western diet for 12 weeks to induce atherosclerosis. Read More

View Article and Full-Text PDF

Decoding empagliflozin's molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence.

Sci Rep 2021 Jun 8;11(1):12025. Epub 2021 Jun 8.

Heart Institute, Hospital Universitari Germans Trias I Pujol, Carretera de Canyet S/N, 08916, Badalona, Spain.

The use of sodium-glucose co-transporter 2 inhibitors to treat heart failure with preserved ejection fraction (HFpEF) is under investigation in ongoing clinical trials, but the exact mechanism of action is unclear. Here we aimed to use artificial intelligence (AI) to characterize the mechanism of action of empagliflozin in HFpEF at the molecular level. We retrieved information regarding HFpEF pathophysiological motifs and differentially expressed genes/proteins, together with empagliflozin target information and bioflags, from specialized publicly available databases. Read More

View Article and Full-Text PDF

Paradigm shift in heart failure treatment: are cardiologists ready to use gliflozins?

Heart Fail Rev 2021 Jun 7. Epub 2021 Jun 7.

Cardiology Section, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.

Despite recent advances in chronic heart failure (HF) therapy, the prognosis of HF patients remains poor, with high rates of HF rehospitalizations and death in the early months after discharge. This emphasizes the need for incorporating novel HF drugs, beyond the current approach (that of modulating the neurohumoral response). Recently, new antidiabetic oral medications (sodium-glucose cotransporter 2 inhibitors (SGLT2i)) have been shown to improve prognosis in diabetic patients with previous cardiovascular (CV) events or high CV risk profile. Read More

View Article and Full-Text PDF

Empagliflozin Significantly Prevents the Doxorubicin-induced Acute Cardiotoxicity via Non-antioxidant Pathways.

Cardiovasc Toxicol 2021 Jun 5. Epub 2021 Jun 5.

Department of Physiology, Faculty of Medicine, Hacettepe University, School of Medicine, Sihhiye, Ankara, Turkey.

Empagliflozin (EMPA) is a SGLT-2 inhibitor that has positive effects on cardiovascular outcomes. In this study, we aim to evaluate the possible protective effects of EMPA against doxorubicin (DOX)-induced acute cardiotoxicity. Non-diabetic Sprague-Dawley rats were randomized into four groups. Read More

View Article and Full-Text PDF

SGLT-2 inhibitors: A step forward in the treatment of heart failure with reduced ejection fraction.

Rev Port Cardiol (Engl Ed) 2021 May 31. Epub 2021 May 31.

CINTESIS - Centro de Investigação em Tecnologias e Serviços de Saúde, Porto, Portugal; Serviço de Cardiologia, Hospital das Forças Armadas - Pólo do Porto, Portugal.

Heart failure (HF) is a major health problem with a significant impact on morbidity, mortality, quality of life and healthcare costs. Despite the positive impact of disease-modifying therapies developed over the last four decades, HF mortality and hospitalization remain high. We aim at reviewing the evidence supporting the use of sodium-glucose co-transporter-2 (SGLT-2) inhibitors, as a novel strategy for HF with reduced ejection fraction (HFrEF) treatment. Read More

View Article and Full-Text PDF

Cardiovascular Outcome Trials with Glucose-Lowering Drugs.

Curr Cardiol Rep 2021 Jun 3;23(7):75. Epub 2021 Jun 3.

AdventHealth Translational Research Institute, 301 E. Princeton Street, Orlando, FL, 32804, USA.

Purpose Of Review: This review summarizes recent cardiovascular outcome trials (CVOTs) with glucose-lowering drugs.

Recent Findings: The majority of recent CVOTs with glucose-lowering drugs have tested dipeptidyl peptidase-4 inhibitors (DPP4-i), glucagon-like peptide-1 receptors agonists (GLP1-RA), and sodium-glucose cotransporter 2 inhibitors (SGLT2i), but studies have also been performed with other agents including thiazolidinediones and insulin. All CVOTs with DPP4-I, GLP1-RA, and SGLT2-i have demonstrated the cardiovascular (CV) safety of these agents compared to usual care. Read More

View Article and Full-Text PDF

SGLT2 Inhibitors, What the Emergency Physician Needs to Know: A Narrative Review.

J Clin Med 2021 May 10;10(9). Epub 2021 May 10.

Service of Cardiology, Cardiovascular Department, Lausanne University Hospital, 1011 Lausanne, Switzerland.

Canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin belong to a class of antidiabetic treatments referred to as sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors, or SGLT2is). SGLT2is are currently indicated in North America and in Europe in type 2 diabetes mellitus, especially in patients with cardiovascular (CV) disease, high CV risk, heart failure, or renal disease. In Europe, dapagliflozin is also approved as an adjunct to insulin in patients with type 1 diabetes mellitus. Read More

View Article and Full-Text PDF

Empagliflozin Inhibits IL-1β-Mediated Inflammatory Response in Human Proximal Tubular Cells.

Int J Mol Sci 2021 May 11;22(10). Epub 2021 May 11.

Department of Internal Medicine IV-Nephrology and Hypertension, Medical University Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria.

SGLT2 inhibitor-related nephroprotection is-at least partially-mediated by anti-inflammatory drug effects, as previously demonstrated in diabetic animal and human studies, as well as hyperglycemic cell culture models. We recently presented first evidence for anti-inflammatory potential of empagliflozin (Empa) under normoglycemic conditions in human proximal tubular cells (HPTC) by demonstrating Empa-mediated inhibition of IL-1β-induced MCP-1/CCL2 and ET-1 expression on the mRNA and protein level. We now add corroborating evidence on a genome-wide level by demonstrating that Empa attenuates the expression of several inflammatory response genes in IL-1β-induced (10 ng/mL) normoglycemic HPTCs. Read More

View Article and Full-Text PDF

Low-Dose Empagliflozin Improves Systolic Heart Function after Myocardial Infarction in Rats: Regulation of MMP9, NHE1, and SERCA2a.

Int J Mol Sci 2021 May 21;22(11). Epub 2021 May 21.

Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Pharmacology, Center for Cardiovascular Research (CCR), 10115 Berlin, Germany.

The effects of the selective sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin in low dose on cardiac function were investigated in normoglycemic rats. Cardiac parameters were measured by intracardiac catheterization 30 min after intravenous application of empagliflozin to healthy animals. Empagliflozin increased the ventricular systolic pressure, mean pressure, and the max dP/dt ( < 0. Read More

View Article and Full-Text PDF

In HFrEF, adding empagliflozin to medical therapy reduced a composite outcome, regardless of CKD status.

Ann Intern Med 2021 Jun 1. Epub 2021 Jun 1.

McMaster University, Hamilton, Ontario, Canada (H.G.V.).

Source Citation: Zannad F, Ferreira JP, Pocock SJ, et al. Circulation. 2021;143:310-21. Read More

View Article and Full-Text PDF

Economic Spectrofluorometric Bioanalysis of Empagliflozin in Rats' Plasma.

J Anal Methods Chem 2021 11;2021:9983477. Epub 2021 May 11.

Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Ain Shams University, Organization of African Unity Street, Abassia, Cairo 11566, Egypt.

A simple, economic, green, and sensitive bioanalytical method for empagliflozin bioassay in rats' plasma was employed successfully owing to the empagliflozin native fluorescence behavior. Enhanced liquid-liquid extraction, using diethyl ether (DEE), was successfully employed for the improved extraction of empagliflozin from rats' plasma based on its high value of logP as 1.8 that boosted the drug migration from plasma to the organic layer. Read More

View Article and Full-Text PDF

Regional Distribution of Cardiologists and Prescription Patterns of Sodium-Glucose Transporter-2 Inhibitors in Japan.

Int Heart J 2021 ;62(3):592-600

Division of Nephrology and Endocrinology, Graduate School of Medicine, The University of Tokyo.

The clinical evidence is accumulating since 2015 that anti-diabetic sodium-glucose cotransporter 2 (SGLT2) inhibitors have the beneficial effect of cardiovascular and, recently, renal protection. Although it is not well analyzed how the transfer of this new evidence into daily practice has expedited, we hypothesize that the recent usage of the drugs is positively associated with several certified cardiologists in each region.The 2016 annual and 2016-2017 increased number of SGLT2 inhibitor tablets, based on the National Database of Health Insurance Claims and Specific Health Checkups of Japan, were divided by the estimated number of patients with type 2 diabetes mellitus for each of the 47 prefectures. Read More

View Article and Full-Text PDF

Concentration-Dependent Clinical and Prognostic Importance of High-Sensitivity Cardiac Troponin T in Heart Failure and a Reduced Ejection Fraction and the Influence of Empagliflozin: the EMPEROR-Reduced Trial.

Eur J Heart Fail 2021 May 30. Epub 2021 May 30.

Université de Lorraine, Inserm INI-CRCT, CHRU, Nancy, France.

Background: Circulating troponin is an important measure of risk in patients with heart failure, but it has not been used to determine if disease severity influences the responses to drug treatments in randomized controlled trials.

Methods: In the EMPEROR-Reduced trial, patients with class II-IV heart failure and a reduced ejection fraction were randomly assigned to placebo or empagliflozin 10 mg daily and followed for the occurrence of serious heart failure and renal events. High-sensitivity cardiac troponin T (hs-cTnT) was measured in 3636 patients (> 97%) at baseline, and patients were divided into four groups based on the degree of troponin elevation. Read More

View Article and Full-Text PDF

Empagliflozin and neohesperidin mitigate methotrexate hepatotoxicity via Nrf2/PPARγ/HO-1 signalling initiation and suppression of NF-κB/Keap1/HSP70/caspase-3 axis in rats.

Life Sci 2021 May 27;278:119638. Epub 2021 May 27.

Department of Pharmacology & Toxicology, Faculty of Pharmacy, Al-Azhar University, Assiut Branch, Assiut 71524, Egypt; Department of Pharmacology & Toxicology, Faculty of Pharmacy, Deraya University, Minya 61519, Egypt.

Hepatotoxicity is the main adverse effect of methotrexate (MTX), which limits its clinical use and effectiveness. Both empagliflozin (EMPA) and neohesperidin dihydrochalcone (NHD) have promising criteria for suppressing oxidative stress, inflammation and apoptosis. In this current study, we suggested that EMPA and NHD exhibit protective effects against MTX-triggered liver injury, considering N-acetylcysteine (NAC) as a reference standard. Read More

View Article and Full-Text PDF

High-Dose Sodium-Glucose Co-transporter 2 Inhibitors are Superior in Type 2 Diabetes: A Meta-analysis of Randomised Clinical Trials.

Diabetes Obes Metab 2021 May 28. Epub 2021 May 28.

Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.

Aims: This study aimed to determine the overall efficacy of high-dose versus low-dose SGLT2 inhibitors in patients with type 2 diabetes mellitus (T2DM).

Material And Methods: A literature search using MEDLINE, EMBASE, and Cochrane Library was performed between 1 January 2006 and 23 September 2020. Random-effects models were used to calculate mean differences (MDs) and pooled relative risk (RR). Read More

View Article and Full-Text PDF

Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis.

Diabetes Obes Metab 2021 May 28. Epub 2021 May 28.

Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Aim: To compare the effects of glucose-lowering drugs on body weight and blood pressure in adults with type 2 diabetes.

Methods: We searched Medline, Embase, the Cochrane Library, and grey literature sources until September 29, 2020 for randomized controlled trials of at least 24 weeks' duration assessing the effects of glucose-lowering drugs on body weight and blood pressure in adults with type 2 diabetes. We did frequentist network meta-analyses and calculated weighted mean differences and 95% confidence intervals combining trial arms of different approved doses of a given intervention into a single group. Read More

View Article and Full-Text PDF

Development and validation of a risk prediction model for in-hospital major cardiovascular events in patients hospitalised for acute myocardial infarction.

BMJ Open 2021 05 27;11(5):e042506. Epub 2021 May 27.

National Clinical Research Center for Cardiovascular Diseases, NHC Key Laboratory of Clinical Research for Cardiovascular Medications, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College Fuwai Hospital, Xicheng District, Beijing, China

Objectives: Patients admitted to hospital with acute myocardial infarction (AMI) have considerable variability in in-hospital risks, resulting in higher demands on healthcare resources. Simple risk-assessment tools are important for the identification of patients with higher risk to inform clinical decisions. However, few risk assessment tools have been built that are suitable for populations with AMI in China. Read More

View Article and Full-Text PDF

[Practical considerations in the use of SGLT2 inhibitors in cardiovascular diseases].

Rev Med Suisse 2021 May;17(740):1034-1038

Service de cardiologie, CHUV, 1011 Lausanne.

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a class of drugs which offer cardiovascular (CV) and renal benefits. They are currently indicated as first-line treatments of type 2 diabetes mellitus (T2DM) in patients with CV disease, high CV risk, renal disease, or heart failure with reduced ejection fraction (HFrEF). Two randomized clinical trials have shown the benefits of dapagliflozin and empagliflozin in patients with HFrEF, regardless of the presence of T2DM. Read More

View Article and Full-Text PDF

Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness Study.

J Am Heart Assoc 2021 Jun 25;10(11):e019356. Epub 2021 May 25.

Department of Clinical Epidemiology Aarhus University Hospital Aarhus Denmark.

Background In cardiovascular outcome trials, the sodium glucose cotransporter 2 inhibitor empagliflozin and glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide caused similar reductions in major adverse cardiac events (MACE). We compared clinical outcomes in routine clinical care. Methods and Results EMPLACE (Cardiovascular and Renal Outcomes, and Mortality in Danish Patients with Type 2 Diabetes Who Initiate Empagliflozin Versus GLP-1RA: A Danish Nationwide Comparative Effectiveness Study) is an ongoing nationwide population-based comparative effectiveness cohort study in Denmark. Read More

View Article and Full-Text PDF

Use of diuretics and outcomes in patients with type 2 diabetes: Findings from the EMPA-REG OUTCOME trial.

Eur J Heart Fail 2021 May 24. Epub 2021 May 24.

Robertson Centre for Biostatistics, University of Glasgow, Glasgow, United Kingdom of Great Britain & Northern Ireland.

Background: Loop diuretics (LD) relieve symptoms and signs of congestion due to heart failure (HF), but many patients prescribed LD do not have such a diagnosis.

Aims And Methods: We studied the relationship between HF diagnosis, use of LD, and outcomes in four patient subgroups with type-2 diabetes mellitus (T2DM) in EMPA-REG OUTCOME; [i) investigator-reported HF on LD, ii) investigator-reported HF not on LD, iii] no HF on LD, and iv) no HF and not on LD], and assessed their risk of CV events.

Results: Of 7,020 participants, at baseline, 706 (10%) had a diagnosis of HF, of whom 334 were prescribed LD. Read More

View Article and Full-Text PDF

Empagliflozin therapy and insulin resistance-associated disorders: effects and promises beyond a diabetic state.

Arch Med Sci Atheroscler Dis 2021 12;6:e57-e78. Epub 2021 Apr 12.

Internal Medicine and Diabetes Clinic, Paphos, Cyprus.

Empagliflozin is a SGLT2 inhibitor that has shown remarkable cardiovascular and renal activities in patients with type 2 diabetes (T2D). Preclinical and clinical studies of empagliflozin in T2D population have demonstrated significant improvements in body weight, waist circumference, insulin sensitivity, and blood pressure - effects beyond its antihyperglycaemic control. Moreover, several studies suggested that this drug possesses significant anti-inflammatory and antioxidative stress properties. Read More

View Article and Full-Text PDF

Does the cardioprotective effect of Empagliflozin involve inhibition of the sodium-proton exchanger?

Cardiovasc Res 2021 May 20. Epub 2021 May 20.

Unit of Cardiac Physiology Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.

View Article and Full-Text PDF

The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007-3015.

Diabetes Care 2021 May 20. Epub 2021 May 20.

Ruth and Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.

View Article and Full-Text PDF

Usefulness of Sodium-Glucose Cotransporter 2 Inhibitors for Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus.

Am J Cardiol 2021 Jul 15;150:65-68. Epub 2021 May 15.

Diabetes Clinic, Central District, Maccabi Healthcare Services, Israel; Sackler Faculty of Medicine, Tel Aviv University, Israel.

The sodium-glucose cotransporter 2 inhibitors (SGLT2i) empagliflozin, canagliflozin, and dapagliflozin reduce the risk of heart failure (HF) events in patients with diabetes mellitus (DM) at high risk for HF. Differences in HF outcomes between SGLT2i were demonstrated in a recent-published meta-analysis. Nevertheless, comparative cost-effectiveness analyses of SGLT2i provided for this indication have not been published yet. Read More

View Article and Full-Text PDF

Comparison of New Oral Hypoglycemic Agents on Risk of Urinary Tract and Genital Infections in Type 2 Diabetes: A Network Meta-analysis.

Adv Ther 2021 Jun 17;38(6):2840-2853. Epub 2021 May 17.

Department of General Medicine, Xiyuan Hospital, China Academy of Chinese Medical Sciences, No. 1, Xiyuan Playground, Zhong Zhi Road, Hai Dian District, Beijing, 100091, China.

Introduction: Dipeptidyl peptidase 4 (DPP4) inhibitors and sodium-glucose co-transporter 2 (SGLT2) inhibitors have often been used for patients with T2DM because of the reduced risk of hypoglycemia. However, DPP4 inhibitors and SGLT2 inhibitors may increase the risk of infectious diseases. This network meta-analysis (NMA) was performed to investigate the risk of urinary tract and genital infections associated with the use of two new glucose-lowering drug classes in patients with type 2 diabetes. Read More

View Article and Full-Text PDF